In our hands, this evidence has been also confirmed showing that not only mTOR inhibitors but also generic treatments able to increase intracellular ROS can overcome resistance to TMZ in glioma cells by inducing CMA activity [8,9]. Here, MTOR is linked to central nervous system cancer.